# ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or

> **NCT04730388** · — · UNKNOWN · sponsor: **University Hospital, Brest** · enrollment: 100 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04730388
- **Lead sponsor:** University Hospital, Brest
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-18
- **Primary completion:** 2022-01-18
- **Final completion:** 2022-01-18
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2021-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04730388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04730388, "ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04730388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*